You are here

  • Home
  • Archive
  • Volume 98, Issue 7
  • Increasing human papilloma virus (HPV) vaccination uptake in people living with HIV: the need to improve both clinician training and health promotion

Article Text

Article menu
Download PDFPDF
Research letter
Increasing human papilloma virus (HPV) vaccination uptake in people living with HIV: the need to improve both clinician training and health promotion
  1. Miriam Ringshall1,
  2. Caroline Cable1,
  3. Colin Fitzpatrick1,
  4. Daniel Richardson1,2
  1. 1 Sexual Health & HIV, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
  2. 2 Brighton and Sussex Medical School, Brighton, UK
  1. Correspondence to Dr Daniel Richardson, University Hospitals Sussex NHS Foundation Trust, Brighton, BN1 9RH, UK; docdanielr{at}hotmail.com

https://doi.org/10.1136/sextrans-2021-055293

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Human papilloma virus (HPV) vaccination is recommended for some people living with HIV (PLWHIV) including men who have sex with men (MSM) up to 45 years old.1 HIV clinics are well placed to deliver HPV vaccination due to patients’ regular attendance for routine monitoring and other health interventions. There is little recent evidence on the uptake and barriers to HPV vaccination in PLWHIV.2 A recent meta-analysis suggested that MSM are receptive to HPV vaccination, but vaccine uptake and completion are below prediction, and additional support and resources are needed to provide optimal vaccination rates.3 Uptake of HPV vaccination in MSM is dependent on both patient perceptions of HPV vaccination and clinician beliefs and offer of vaccine to patients.4–8

    As part of a service development project, we reviewed the records of MSM under 46 years who attended for HIV care between January 2020 and June 2021. A random selection …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors DR, CF and CC designed the study. MR, CC and CF analysed the data. DR, MR, CC and CF contributed to data collection and contributed to the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.